Back to search >>
Mabat Amok Mabat Amok Back to search >>
What have we accomplished?
The project was started as university research from building the prototype ALFA. A year and a half took a set of statistics. A year on the development and verification of the algorithm which is able to separate the spectral signatures of melanoma from non-melanoma the prototype alpha already gives a correct diagnosis, regardless of the skill and qualifications of the doctor. With our diagnostic algorithm, developed based on the measured data, the probability of a correct diagnosis of the disease is 100%, but it has 16% false positive. The stages are defined in the earliest melanoma spreading where spectral registration is possible. The project is based on an accumulated intellectual foundation:
Dermatology devises market worth over $17 billion by 2024: Global Market Insights, Inc.
Diagnostic devices held more than 55% of industry revenue share in 2017 due to growing incidence of skin cancer and rising need for early disease detection
Goldstein Research analyst forecast the melanoma scanner market size is set to reach USD 850 million by 2025, at a CAGR of 7.6% over the forecast period
Cancer of the skin is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths The ACS’s estimates for melanoma in the United States for 2019 are:
About 96,480 new melanomas will be diagnosed
(about 57,220 in men and 39,260 in women)
About 7,230 people are expected to die of melanoma (about 4,740 men and 2,490 women)
Because early detection is critical to survival, the American Cancer Society recommends that all Americans over the age of 20 undergo complete skin examinations during their periodic health check-ups.
Early Detection - $1,800 USD
Advanced Stage - $155,000 USD
Cost of the unit: $3000
Price per unit: ~ $3000
Price per test: ~ $1
What’s our strategic goal?
Mabat Amok aims to develop the tissue spectroscopy platform, based on hospital-proven technology, which enables a real-time noninvasive reliable device for early melanoma detection on a compact device.
What have we accomplished?
The project was started as university research from building the prototype ALFA. A year and a half took a set of statistics. A year on the development and verification of the algorithm which is able to separate the spectral signatures of melanoma from non-melanoma the prototype alpha already gives a correct diagnosis, regardless of the skill and qualifications of the doctor. With our diagnostic algorithm, developed based on the measured data, the probability of a correct diagnosis of the disease is 100%, but it has 16% false positive. The stages are defined in the earliest melanoma spreading where spectral registration is possible. The project is based on an accumulated intellectual foundation:...
Read More....
Mabat Amok aims to develop the tissue spectroscopy platform, based on hospital-proven technology, which enables a real-time noninvasive reliable device for early melanoma detection on a compact device.
What have we accomplished?
The project was started as university research from building the prototype ALFA. A year and a half took a set of statistics. A year on the development and verification of the algorithm which is able to separate the spectral signatures of melanoma from non-melanoma the prototype alpha already gives a correct diagnosis, regardless of the skill and qualifications of the doctor. With our diagnostic algorithm, developed based on the measured data, the probability of a correct diagnosis of the disease is 100%, but it has 16% false positive. The stages are defined in the earliest melanoma spreading where spectral registration is possible. The project is based on an accumulated intellectual foundation:...
What have we accomplished?
The project was started as university research from building the prototype ALFA. A year and a half took a set of statistics. A year on the development and verification of the algorithm which is able to separate the spectral signatures of melanoma from non-melanoma the prototype alpha already gives a correct diagnosis, regardless of the skill and qualifications of the doctor. With our diagnostic algorithm, developed based on the measured data, the probability of a correct diagnosis of the disease is 100%, but it has 16% false positive. The stages are defined in the earliest melanoma spreading where spectral registration is possible. The project is based on an accumulated intellectual foundation:
- Accumulated database (62 patients)
- Formed understanding of how disease spreading effects on the tissue’s optical properties
- The stage of melanoma in which the spectral differences are possible to register (Spectral Threshold)
- Defined spectral intervals
- Existing algorithm
- Insurance companies
- Hospitals and Clinics.
- Dermatologists.
- Plastic surgery
- Family Physician.
- Drug developers/monitoring emerging drugs
- Cosmetics market
- Compact.
- Cheap.
- Low cost per test unit.
- Diagnoses in real-time.
- Allows for comparative analysis at short intervals.
- Positioned to create a network across the country.
- Very easy to use, even by non-medical personnel.
- Just like blood pressure monitors and scales, the access to the device can be out in the open and is to be located outside of the doctor’s office, where other medical and non-medical staff can assist the patient with the test.
- The correct diagnosis is independent of the individual’s qualifications performing the test.
- The large capacity of the device will ensure mass coverage and prevent misdiagnosis of the disease.
Dermatology devises market worth over $17 billion by 2024: Global Market Insights, Inc.
Diagnostic devices held more than 55% of industry revenue share in 2017 due to growing incidence of skin cancer and rising need for early disease detection
Goldstein Research analyst forecast the melanoma scanner market size is set to reach USD 850 million by 2025, at a CAGR of 7.6% over the forecast period
Cancer of the skin is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths The ACS’s estimates for melanoma in the United States for 2019 are:
About 96,480 new melanomas will be diagnosed
(about 57,220 in men and 39,260 in women)
About 7,230 people are expected to die of melanoma (about 4,740 men and 2,490 women)
Because early detection is critical to survival, the American Cancer Society recommends that all Americans over the age of 20 undergo complete skin examinations during their periodic health check-ups.
Early Detection - $1,800 USD
Advanced Stage - $155,000 USD
Cost of the unit: $3000
Price per unit: ~ $3000
Price per test: ~ $1
What’s our strategic goal?
- Mabat Amok is committed to bringing to the market a real-time diagnostic instrument for fast non-invasive early diagnosis of melanoma.
- This diagnostic instrument focused on objective differences between spectral properties of melanoma and benign pigment moles.
- Our research team consists of highly skilled professionals with years of experience, which specialize in skin cancer detections.
- This diagnostic instrument will be used as a part of the routine medical practice for early detection of skin melanoma and other skin cancers, as well as, treatment and monitoring of patients with such diseases.
- Portfolio investment of $1М for one-year prototype Betta.
- Over the course of three years, the company will complete clinical trials and test approximately 1000 patients, amongst which several hundred will have a proven skin cancer condition.
- Based on the existing prototype Alpha, an industrial prototype Beta will be created.
Entrepreneurs
Entrepreneurs
